We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DNA Electronics Appoints Nick McCooke as Chief Business Officer
News

DNA Electronics Appoints Nick McCooke as Chief Business Officer

DNA Electronics Appoints Nick McCooke as Chief Business Officer
News

DNA Electronics Appoints Nick McCooke as Chief Business Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DNA Electronics Appoints Nick McCooke as Chief Business Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DNA Electronics Ltd (DNAe) has announced the appointment of Nick McCooke as Chief Business Officer as it continues to build its management team.

Mr McCooke brings 30 years of senior management experience in Healthcare businesses. As CEO of Solexa, from its spin-out from the University of Cambridge in 2000 to its NASDAQ listing in 2005, he led the development of the world’s leading Next Generation DNA Sequencing (NGS) technology, which is the basis of Illumina’s current product line.

Mr McCooke comments: “I’m thrilled to be joining DNAe at this exciting point in the company’s evolution. I was proud to be part of the NGS revolution ten years ago and I believe that bringing the technology to clinicians at the point of need is the next revolution.”

CEO and Chairman Prof. Chris Toumazou adds: “This is a key appointment for DNAe, as we build a world-class management team to bring our Genalysis® molecular diagnostics platform to market. Nick’s experience, both in NGS technology and in the diagnostics markets will help us to develop ground-breaking new products that give clinicians rapid actionable diagnosis of life-threatening conditions.”

Advertisement